CEPTAZ
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEPTAZ is an injectable small-molecule antibiotic approved by GSK in 1990 for bacterial infections. The drug is administered via injection and represents a mature treatment option in the anti-infective space. Specific mechanism of action and approved indications are not detailed in available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100); brand team focus likely shifting to managed decline or line extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CEPTAZ offers limited career growth given its LOE-approaching status and zero linked job openings. This assignment is best suited for professionals seeking stable, maintenance-oriented work or those transitioning portfolios rather than high-impact launch or growth roles.
Brand ManagerSenior Sales Representative
Worked on CEPTAZ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.